Dm values in various human leukemic and murine hematopoietic cell lines obtained by MTT proliferation assays
Cell line . | Imatinib, μM . | Decitabine, μM . | As2O3, μM . |
|---|---|---|---|
| K562 | 0.3 ± 0.1 | 1.33 ± 1.22 | 1.1 ± 0.12 |
| MO7e | > 10 | 0.033 ± 0.02 | 0.81 ± 0.18 |
| MO7p210 | 0.071 ± 0.022 | 1.25 ± 1.08 | 1.99 ± 0.18 |
| 32D | > 10 | 0.59 ± 0.17 | 0.52 ± 0.18 |
| 32Dp210 | 0.14 ± 0.036 | 0.58 ± 0.3 | 0.29 ± 0.09 |
| AR230-s | 0.15 ± 0.08* | 0.15 ± 0.04 | 2.6 ± 0.51 |
| AR230-r | 1.56 ± 0.12* | 0.31 ± 0.09 | 0.94 ± 0.13 |
| Baf/BCR-ABL-s | 0.38 ± 0.05 | 0.92 ± 0.04 | 0.28 ± 0.05 |
| Baf/BCR-ABL-r | 2.23 ± 0.26* | 0.96 ± 0.07 | 0.35 ± 0.05 |
| Ba/F3p210Y253F | 2.50 ± 0.63 | 0.60 ± 0.21 | 0.28 ± 0.03 |
| Ba/F3p210T315I | > 10 | 1.16 ± 0.56 | 0.31 ± 0.07 |
| Ba/F3p210M351T | 0.93 ± 0.16 | 0.74 ± 0.11 | 0.27 ± 0.02 |
Cell line . | Imatinib, μM . | Decitabine, μM . | As2O3, μM . |
|---|---|---|---|
| K562 | 0.3 ± 0.1 | 1.33 ± 1.22 | 1.1 ± 0.12 |
| MO7e | > 10 | 0.033 ± 0.02 | 0.81 ± 0.18 |
| MO7p210 | 0.071 ± 0.022 | 1.25 ± 1.08 | 1.99 ± 0.18 |
| 32D | > 10 | 0.59 ± 0.17 | 0.52 ± 0.18 |
| 32Dp210 | 0.14 ± 0.036 | 0.58 ± 0.3 | 0.29 ± 0.09 |
| AR230-s | 0.15 ± 0.08* | 0.15 ± 0.04 | 2.6 ± 0.51 |
| AR230-r | 1.56 ± 0.12* | 0.31 ± 0.09 | 0.94 ± 0.13 |
| Baf/BCR-ABL-s | 0.38 ± 0.05 | 0.92 ± 0.04 | 0.28 ± 0.05 |
| Baf/BCR-ABL-r | 2.23 ± 0.26* | 0.96 ± 0.07 | 0.35 ± 0.05 |
| Ba/F3p210Y253F | 2.50 ± 0.63 | 0.60 ± 0.21 | 0.28 ± 0.03 |
| Ba/F3p210T315I | > 10 | 1.16 ± 0.56 | 0.31 ± 0.07 |
| Ba/F3p210M351T | 0.93 ± 0.16 | 0.74 ± 0.11 | 0.27 ± 0.02 |
Dose-response data were analyzed by the median-effect method, and drug concentrations (μM) required for 50% growth inhibition were calculated (Dm). Values are given as means of at least 3 independent experiments ± standard deviation. Data that did not qualify for the median-effect method (r value less than 0.9) were analyzed by hand (IC50 derivation from the dose-response plot).
IC50 derived by hand.